Table 2.

Difference between the day 3 postdose, time-matched change from baseline in mean QTcF (dQTcF) with GTDS (group 1) and i.v. granisetron (group 2) compared with dQTcF with placebo (ddQTcF, where ddQTcF = dQTcFGTDS − dQTcFplacebo)

GTDSIntravenous granisetron
Postdose time point, hDifference in LS means (90% CI)PDifference in LS means (90% CI)P
01.1 (−3.59, 5.73)0.70311.6 (−2.74, 5.86)0.5486
0.250.2 (−4.36, 4.69)0.9515−1.1 (−5.36, 3.25)0.6847
0.51.7 (−3.10, 6.55)0.5540−0.7 (−5.02, 3.58)0.7828
11.0 (−3.55, 5.46)0.7264−1.2 (−5.54, 3.06)0.6339
21.7 (−3.09, 6.45)0.56100.5 (−3.85, 4.76)0.8604
41.9 (−3.05, 6.88)0.5236−1.0 (−5.33, 3.29)0.6947
80.3 (−4.08, 4.71)0.9050−0.9 (−5.21, 3.39)0.7258
120.4 (−4.21, 4.99)0.8877−0.5 (−4.85, 3.76)0.8344
240.5 (−3.67, 4.61)0.85020.0 (−4.30, 4.31)0.9975
Overall P
 Treatment0.70330.8687
 Time<0.0001<0.0001
 Treatment × time0.97050.8216

Abbreviation: LS, least-squares.